These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 12354600

  • 1. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.
    Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K.
    Am J Surg; 2002 Sep; 184(3):279-83. PubMed ID: 12354600
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M, Sohda M, Miyazaki T, Honjo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Yokobori T, Kuwano H.
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [Abstract] [Full Text] [Related]

  • 3. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
    Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M.
    Ann Surg; 2001 Mar; 233(3):300-9. PubMed ID: 11224616
    [Abstract] [Full Text] [Related]

  • 5. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
    Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1053-9. PubMed ID: 15964705
    [Abstract] [Full Text] [Related]

  • 6. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.
    Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, Kimura H, Faried A, Saito K, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Nonaka T, Shioya M, Ishikawa H, Sakurai H, Nakano T, Kuwano H.
    Anticancer Res; 2007 Nov 15; 27(4C):2627-33. PubMed ID: 17695425
    [Abstract] [Full Text] [Related]

  • 7. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun 15; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 8. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y.
    Ann Surg Oncol; 2014 Feb 15; 21(2):575-82. PubMed ID: 24201746
    [Abstract] [Full Text] [Related]

  • 9. Role of 18F-FDG-PET/CT in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Sasaki K, Uchikado Y, Okumura H, Omoto I, Kita Y, Arigami T, Uenosono Y, Owaki T, Maemura K, Natsugoe S.
    Anticancer Res; 2017 Feb 15; 37(2):859-864. PubMed ID: 28179343
    [Abstract] [Full Text] [Related]

  • 10. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M.
    Ann Surg; 2009 Dec 15; 250(6):888-94. PubMed ID: 19953708
    [Abstract] [Full Text] [Related]

  • 11. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1375-82. PubMed ID: 23219566
    [Abstract] [Full Text] [Related]

  • 12. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D, Yoshida N, Watanabe M, Shiraishi S, Ishimoto T, Kosumi K, Tokunaga R, Taki K, Higashi T, Harada K, Miyata T, Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yamashita Y, Baba H.
    J Gastroenterol; 2016 Aug 01; 51(8):788-95. PubMed ID: 26671045
    [Abstract] [Full Text] [Related]

  • 13. Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus.
    Dewan A, Sharma SK, Dewan AK, Khurana R, Gupta M, Pahuja A, Srivastava H, Sinha R.
    J Gastrointest Cancer; 2017 Mar 01; 48(1):42-49. PubMed ID: 27604122
    [Abstract] [Full Text] [Related]

  • 14. Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
    Kaderi ASA, Sabita J, Tiwari VK, Pawar A, Niyogi D.
    J Gastrointest Cancer; 2024 Jun 01; 55(2):820-828. PubMed ID: 38308686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma.
    Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K.
    Cancer; 2002 Feb 15; 94(4):921-8. PubMed ID: 11920459
    [Abstract] [Full Text] [Related]

  • 17. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul 15; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW.
    Ann Surg; 2006 Apr 15; 243(4):472-8. PubMed ID: 16552197
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.